Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Erin Duhaime

Physician Assistant, Medical Dallas, TX Physician Assistant

NPI 1801041009 CMS profile 10738602

3500 Oak Lawn Ave, Ste 700, Dallas, TX 75219

Open in the dashboard

General payments

$149,540

875 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erin Duhaime of Dallas, TX is reported in the CMS Open Payments database as having received $149,540 across 875 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $43,741 194
2024 General $52,323 198
2023 General $34,787 191
2022 General $14,797 180
2021 General $3,892 112

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erin Duhaime
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Erin Duhaime were reported at $43,741. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Erin Duhaime Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $3,892 $156 $41–$563 $132
2022 $14,797 $185 $55–$649 $149
2023 $34,787 $199 $58–$717 $160
2024 $52,323 $206 $62–$740 $164
2025 $43,741 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ViiV Healthcare Company $107,390 405 payments
  2. Ferring Pharmaceuticals Inc. $21,514 39 payments
  3. Merck Sharp & Dohme Corporation $11,057 63 payments
  4. Gilead Sciences, Inc. $2,671 73 payments
  5. Theratechnologies Inc. $928 25 payments
  6. AbbVie, Inc. $818 40 payments
  7. Janssen Research & Development, LLC $620 8 payments
  8. Insmed, Inc. $614 25 payments
  9. Shionogi Inc $462 27 payments
  10. Astellas Pharma US Inc $443 17 payments
  11. Other $3,022 153 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $96,312 69 payments
  2. Food and Beverage $23,160 729 payments
  3. Travel and Lodging $20,771 60 payments
  4. Consulting Fee $7,580 7 payments
  5. Education $1,717 10 payments
Products named General payments · program years 2021–2025
  1. APRETUDE Hiv $54,918 102 payments
  2. REBYOTA $21,514 39 payments
  3. APRETUDE Hiv $20,724 55 payments
  4. DOVATO $18,499 120 payments
  5. PIFELTRO $10,718 46 payments
  6. CABENUVA Hiv $2,980 22 payments
  7. CABENUVA Hiv $2,488 55 payments
  8. TROGARZO $928 25 payments
  9. Arikayce $614 25 payments
  10. SYMTUZA $606 25 payments
  11. Other $6,925 342 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 82 drugs

Part D claims

3,028

Median for Physician Assistant: 241

Drug cost

$3,871,076

Median for Physician Assistant: $4,110

Branded share of claims

51.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 170 $697,681
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 112 $548,058
Dovato Dolutegravir Sodium/Lamivudine Brand 161 $495,581
Triumeq Abacavir/Dolutegravir/Lamivudi Brand 80 $327,660
Pifeltro Doravirine Brand 150 $277,398
Tivicay Dolutegravir Sodium Brand 91 $229,381
Rukobia Fostemsavir Tromethamine Brand 20 $199,205
Prezcobix Darunavir/Cobicistat Brand 80 $197,562
Descovy Emtricitabine/Tenofov Alafenam Brand 80 $181,174
Cabenuva Cabotegravir/Rilpivirine Brand 27 $174,969

The 10 drugs with the highest cost, of 82 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$19,473

Medicare's payments for the services billed

Medicare patients

61

Average age 68

Services billed

2,396

24 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Depression 43%
Chronic kidney disease 36%
Diabetes 33%
Cancer 30%
Heart failure 28%
Ischemic heart disease 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
APRETUDE
  • ViiV Healthcare Company $34,423
$34,423 — —
DOVATO
  • ViiV Healthcare Company $7,467
$7,467 161 —
REBYOTA
  • Ferring Pharmaceuticals Inc. $3,894
$3,894 — —
PIFELTRO
  • Merck Sharp & Dohme Corporation $1,872
$1,872 150 —
CABENUVA
  • ViiV Healthcare Company $214
$214 27 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

875 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record